AI drug discovery’s 80-90% Phase I success rate is real. But Phase I mostly measures toxicity. The industry is betting billions on a revolution whose hardest proof is still outstanding.
AI agents are proliferating across clinical settings faster than any validation framework can track — and a new BCBS study showing $663 million in AI-inflated billing is just the opening act.
As major AI companies race into healthcare with sophisticated tools, the critical question isn’t just capability—it’s whether innovation can coexist with the human touch that defines quality care.
Horizon 1000’s ambitious plan to bring AI to 1,000 African clinics by 2028 forces us to confront both AI’s potential and the structural inequities that threaten its success.
Slingshot AI’s UK withdrawal reveals the urgent need for clear regulatory frameworks governing AI mental health tools operating in the gray zone between wellness apps and medical devices.
The January 2026 launches of ChatGPT Health and Claude for Healthcare represent both tremendous promise and serious peril for the future of AI in medicine.
